RT info:eu-repo/semantics/article
T1 Reduction in the risk of peripheral neuropathy and lower decrease in kidney function with metformin, linagliptin or their fixed-dose combination compared to placebo in prediabetes: a randomized controlled trial
A1 Gabriel, Rafael
A1 Boukichou Abdelkader, Nisa
A1 Gilis-Januszewska, Aleksandra
A1 Makrilakis, Konstantinos
A1 Gómez Huelgas, Ricardo
A1 Kamenov, Zdravko
A1 Paulweber, Bernhard
A1 Satman, Ilhan
A1 Djordjevic, Predrag
A1 Alkandari, Abdullah
A1 Mitrakou, Asimina
A1 Lalic, Nebojsa
A1 Egido, Jesús
A1 Más Fontao, Sebastián
A1 Calvet, Jean Henri
A1 Pastor Jimeno, José Carlos
A1 Lindström, Jaana
A1 Lind, Marcus
A1 Acosta, Tania
A1 Silva, Luis
A1 Tuomilehto, Jaakko
K1 Diabetes - Diagnosis
K1 Diabetes - Prevention
K1 Diabetes - Prevención
K1 Diabetes - Treatment
K1 Diabetes - Tratamiento
K1 Nervous system - Diseases
K1 Nervioso, Sistema - Enfermedades
K1 Sistema nervioso periférico - Enfermedades
K1 Neuropatia
K1 Neurology
K1 Kidneys - Diseases
K1 Riñones - Enfermedades
K1 Pharmacology
K1 Drugs
K1 Medicamentos
K1 Lifestyle
K1 Calidad de vida
K1 Clinical trials
K1 Ensayos clínicos
K1 Public health
K1 32 Ciencias Médicas
K1 3205.07 Neurología
K1 3209 Farmacología
K1 3212 Salud Publica
AB Objective: To compare the effect of glucose-lowering drugs on peripheral nerve and kidney function in prediabetes. Methods: Multicenter, randomized, placebo-controlled trial in 658 adults with prediabetes treated for 1 year with metformin, linagliptin, their combination or placebo. Endpoints are small fiber peripheral neuropathy (SFPN) risk estimated by foot electrochemical skin conductance (FESC < 70 μSiemens) and estimated glomerular filtration rate (eGFR). Results: Compared to the placebo, the proportion of SFPN was reduced by 25.1% (95% CI:16.3–33.9) with metformin alone, by 17.3% (95% CI 7.4–27.2) with linagliptin alone, and by 19.5% (95% CI 10.1–29.0) with the combination linagliptin/metformin (p < 0.0001 for all comparisons). eGFR remained +3.3 mL/min (95% CI: 0.38–6.22) higher with the combination linagliptin/metformin than with the placebo (p = 0.03). Fasting plasma glucose (FPG) decreased more with metformin monotherapy −0.3 mmol/L (95%CI: −0.48; 0.12, p = 0.0009) and with the combination metformin/linagliptin −0.2 mmol/L (95% CI: −0.37; −0.03) than with the placebo (p = 0.0219). Body weight (BW) decreased by −2.0 kg (95% CI: −5.65; −1.65, p = 0.0006) with metformin monotherapy, and by −1.9 kg (95% CI: −3.02; −0.97) with the combination metformin/linagliptin as compared to the placebo (p = 0.0002). Conclusions: in people with prediabetes, a 1 year treatment with metformin and linagliptin, combined or in monotherapy, was associated with a lower risk of SFPN, and with a lower decrease in eGFR, than treatment with placebo.
PB MDPI
SN 2077-0383
YR 2023
FD 2023
LK https://uvadoc.uva.es/handle/10324/69310
UL https://uvadoc.uva.es/handle/10324/69310
LA eng
NO Journal of Clinical Medicine, 2023, Vol. 12, Nº. 5, 2035
NO Producción Científica
DS UVaDOC
RD 24-dic-2024